Literature DB >> 12167415

The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma.

Pornchai O-charoenrat1, Peter H Rhys-Evans, Helmout Modjtahedi, Suzanne A Eccles.   

Abstract

c-erbB receptor signalling induces pleiotropic responses and influences several biological functions involved in the pathogenesis and progression of HNSCC. Aberrant expression of multiple c-erbB receptors and ligands is frequently observed in tumour cells. EGFR appears to be a dominant factor controlling the malignant phenotype in HNSCC at least in part via regulation of molecules involved in invasive and angio-/lymphangiogenic processes. Although c-erbB-2 is an orphan receptor, the formation of heterodimer complexes appears to be an important mechanism for inter-receptor activation and synergistic signal transduction. The roles of c-erbB-3 and c-erbB-4 in HNSCC progression are less clear. However, their ability to form heterodimers with other c-erbB family members enhances proliferation and invasion in HNSCC cells. At least two major downstream signalling pathways, MAPK and PI3K, are involved in the transcriptional regulation of proteases and cytokines implicated in invasion and angiogenesis. Studies using clinical specimens confirmed experimental data that co-operative signalling of c-erbB receptors may play a significant role in the pathogenesis of HNSCC. Most therapeutic studies in HNSCC so far have focused on the strategies targeting of EGFR. Due to the complexity of the system both at the receptor and ligand levels and the integrated biological functions of the c-erbB family in HNSCC, the effect of combined c-erbB blockade (or their downstream signalling pathways) on HNSCC progression should be explored.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167415     DOI: 10.1016/s1368-8375(02)00029-5

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  22 in total

1.  Her-2 immunohistochemical expression in oral squamous cell carcinomas is associated with polysomy of chromosome 17, not Her-2 amplification.

Authors:  Dimitrios Papavasileiou; Konstantinos Tosios; Panos Christopoulos; Nikolaos Goutas; Dimitrios Vlachodimitropoulos
Journal:  Head Neck Pathol       Date:  2009-08-22

2.  Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread.

Authors:  Sabrina Daniela Silva; Moulay A Alaoui-Jamali; Michael Hier; Fernando Augusto Soares; Edgard Graner; Luiz Paulo Kowalski
Journal:  Clin Exp Metastasis       Date:  2013-12-15       Impact factor: 5.150

Review 3.  Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer.

Authors:  Ranee Mehra; Ilya G Serebriiskii; Roland L Dunbrack; Matthew K Robinson; Barbara Burtness; Erica A Golemis
Journal:  Drug Resist Updat       Date:  2011-09-14       Impact factor: 18.500

4.  Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: a case control study.

Authors:  Vanessa F Bernardes; Frederico O Gleber-Netto; Sílvia F Sousa; Tarcília A Silva; Maria Cássia F Aguiar
Journal:  J Exp Clin Cancer Res       Date:  2010-04-29

Review 5.  Metastatic disease in head & neck oncology.

Authors:  Paolo Pisani; Mario Airoldi; Anastasia Allais; Paolo Aluffi Valletti; Mariapina Battista; Marco Benazzo; Roberto Briatore; Salvatore Cacciola; Salvatore Cocuzza; Andrea Colombo; Bice Conti; Alberto Costanzo; Laura Della Vecchia; Nerina Denaro; Cesare Fantozzi; Danilo Galizia; Massimiliano Garzaro; Ida Genta; Gabriela Alejandra Iasi; Marco Krengli; Vincenzo Landolfo; Giovanni Vittorio Lanza; Mauro Magnano; Maurizio Mancuso; Roberto Maroldi; Laura Masini; Marco Carlo Merlano; Marco Piemonte; Silvia Pisani; Adriele Prina-Mello; Luca Prioglio; Maria Gabriella Rugiu; Felice Scasso; Agostino Serra; Guido Valente; Micol Zannetti; Angelo Zigliani
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-04       Impact factor: 2.124

Review 6.  The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.

Authors:  Ranee Mehra; Roger B Cohen; Barbara A Burtness
Journal:  Clin Adv Hematol Oncol       Date:  2008-10

7.  Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.

Authors:  Christina I Tsien; Mukesh K Nyati; Aarif Ahsan; Susmita G Ramanand; Douglas B Chepeha; Francis P Worden; Joseph I Helman; Nisha D'Silva; Carol R Bradford; Gregory T Wolf; Theodore S Lawrence; Avraham Eisbruch
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

Review 8.  EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck.

Authors:  Ranee Mehra; Roger B Cohen; Paul M Harari
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

9.  Correlation of c-erbB-2 and S-100 expression with the malignancy grading and anatomical site in oral squamous cell carcinoma.

Authors:  Ricardo L C Albuquerque; Márcia C C Miguel; Antonio L L Costa; Lélia B Souza
Journal:  Int J Exp Pathol       Date:  2003-12       Impact factor: 1.925

10.  Glottic versus supraglottic tumors: differential molecular profile.

Authors:  Konstantinos Kourelis; Theodoros Papadas; Gerasimos Vandoros; Panos Goumas; Georgia Sotiropoulou-Bonikou
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-10-02       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.